SARS-CoV-2 surveillance testing and isolation management of immunocompromised patients: Survey results from 13 health care centers in the United States

As a newly emerging pathogen, infection prevention and isolation management response for SARS-CoV-2 varied greatly by individual health care center. Specific patient population needs, especially those of severely immunocompromised oncologic patients, potentially intensified the response. A survey was distributed to academic health care centers to ascertain surveillance testing frequency, patient placement, and isolation management for patients undergoing cell therapy treatments. •Current SARS-CoV-2 guidance lacks information for patients receiving HCTs.•A survey sent to 13 transplant centers revealed heterogeneity in application of guidance.•Despite differences, transmission events were not reported.